About Us

Company Mission

To be an innovation leader in the healthcare informatics industry, optimizing the treatment of patients by empowering clinicians with time-critical information.

History

VigiLanz was founded in 2001 by two medical doctors with one single-minded purpose: to empower pharmacists, physicians and nurses with tools to proactively monitor their patients to identify and prevent adverse drug events, and support adherence to clinical best practices. Their goal is to protect patients, in real time, from needless harm and pain and suffering, while optimizing care and outcomes. Prevention remains one of the core benefits of their application. And their rationale is that the cost of prevention is only a small fraction of the cost of extended hospital care and other mitigating consequences of preventable ADEs.

Health care providers agree that ADEs and other adverse clinical events cannot be eliminated entirely. But the clinical studies that have been conducted in this area over the last two decades suggest that up to 95 percent of hospital-based adverse events can be prevented with more thorough round-the-clock monitoring (1-5).

Real time patient safety monitoring, once thought to be a luxury few hospitals could afford, is now possible with the VigiLanz Dynamic Monitoring™ System, an automated 24/7 patient monitoring system that so effectively anticipates and detects adverse events—and automatically sends warning alerts to clinicians when they occur—that it can reduce preventable ADEs and other adverse events by 50 percent or more.

Preventing the Preventable

Studies referenced by the Agency for Healthcare Research and Quality (AHRQ) report that ADEs account for an estimated 7,000 deaths each year among U.S. hospital patients, and more than 700,000 injuries (5-7). The July 2006 Institute of Medicine publication, Preventing Medication Errors, estimates that medication errors alone harm 1.5 million people per year and cost hospitals about $3.5 billion annually (20). Adverse drug events occur at a rate of 6.5 to 11.5 per 100 hospital admissions, and can add from $500,000 to $5 million per hospital per year in avoidable expenses (2-3, 8-9).

The full impact of adverse clinical events has been difficult to measure due to the lack of tools that automate the monitoring process. Few hospitals can afford the cost of real time chart review – it is just too labor intensive. Nevertheless, few clinicians debate the need for more efficient and effective monitoring to prevent the preventable. VigiLanz Chairman and CEO David Goldsteen, M.D., and David Klass, M.D., inventor of the core technology, strongly believe that automated monitoring will play a vital role in reducing the incidence of ADEs and other adverse clinical reactions in the future, and will soon be a standard protocol in all hospitals.

The Dynamic Monitoring™ System is the first comprehensive, rules-based software technology that merges the patient’s clinical data with the hospital’s own clinical best practice guidelines to empower clinicians to anticipate, identify and prevent adverse events and optimize clinical outcomes. This forward-looking software works seamlessly with any existing hospital system to send automated alerts directly to clinicians via pager, PDA or e-mail. It takes only 90 days to install, and requires minimal time and effort from one or two members of the hospital’s IT staff during the installation.